What was changed
Abbott decided early in 2020 that the pandemic needed tests that were cheap, fast and mass-producible, not just lab machines. It launched a portfolio across rapid antigen, molecular and antibody platforms, among them BinaxNOW, Panbio and ID NOW.
The company scaled relentlessly: it delivered more than 300 million COVID-19 diagnostic tests in the fourth quarter alone, and worldwide diagnostics sales rose 111% in Q4 2020.
For the full year, total sales rose 8.5% to $34.6 billion while diagnostics grew 40.1% to $10.8 billion; COVID-19 testing-related sales totaled $2.4 billion in Q4, led by $1.9 billion from the three rapid platforms.
What it achieved
Full-year 2020 sales rose 8.5% to $34.6B; diagnostics sales grew 40.1% to $10.8B; Q4 sales rose 28.7% to $10.7B with $2.4B of COVID test sales and 300M tests delivered.
Why it worked
Rapid antigen tests were cheap enough for mass screening, opening a market lab PCR could not fill.
Multiple platforms, rapid, molecular and lab, hedged the uncertainty about which test would win.
Manufacturing scale became the moat: competitors could match a test but not 300 million units a quarter.
What can be applied
A fast-moving crisis rewards speed to a low-cost, high-volume product: Abbott's bet on simple antigen tests at massive scale captured demand that lab-only competitors could not satisfy.
Aftermath
Abbott exited 2020 forecasting 2021 EPS growth of more than 35%, with CEO Robert Ford citing momentum from the tests and the pipeline they funded; the diagnostics franchise the pandemic built stayed its largest business.
FOLLOW THE EVIDENCE